News | Heart Failure | June 23, 2017

First Canadian Patient Implanted With CardioMEMS Heart Failure Sensor

After simple procedure, heart monitor proven to alter treatment of cardiac condition

First Canadian Patient Implanted With CardioMEMS Heart Failure Sensor

June 23, 2017 — In a Canadian first, a medical team has implanted the wireless CardioMEMS HF device inside a heart failure patient. The device permits clinicians to monitor the patient’s cardiovascular status — virtually and in real time ‑ and proactively adjust treatment to prevent costly, potentially unnecessary hospitalization.

“Heart failure is an epidemic that commonly leads to hospitalization,” said Heather Ross, M.D., scientific lead at the Ted Rogers Centre for Heart Research and cardiologist, Peter Munk Cardiac Centre, University Health Network. “Hospitalization is often necessary when patients start to retain fluid, develop congestion and experience shortness of breath. This technology is a way to directly measure how much fluid is in a patient, allowing us to intervene before they develop symptoms of congestion, before they end up in hospital. This is a big game-changer.”

Funded by the Ted Rogers Centre for Heart Research, the CardioMEMS HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017. The system features a small butterfly-like sensor that then sits inside the pulmonary artery of a heart failure patient. When the patient lies on an accompanying antenna-equipped pillow device, the sensor provides important data — including the patient’s lung pressure readings to clinicians — via a secure website.

“Never before have we had the ability to obtain a patient’s accurate lung pressure data while they are outside the hospital,” said Meredith Linghorne, nurse practitioner, Peter Munk Cardiac Centre. “Traditionally we’ve relied on a patient describing symptoms, and by then they may have already progressed to the point of hospitalization. With this device, we can see warning signs days in advance, and adjust treatment accordingly.”

The most rapidly rising cardiovascular disease in Canada, heart failure affects close to one million Canadians, and an estimated 26 million people globally. In Canada, heart failure patients stay an average of almost 10 days for each hospital admission, accounting for 1.4 million hospital stays a year. These patients live an average of 2.1 years after diagnosis and cost the Canadian health-care system more than $3 billion annually. About one-quarter of these patients return to hospital within three months, while approximately 50 per cent return to hospital within six months.

The CardioMEMS HF System is designed to remotely monitor heart failure patients whose condition is serious but who are not so ill that the technology cannot improve their outcome. The first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.

Produced by Abbott, the CardioMEMS HF System is approved in the United States by the U.s. Food & Drug Administration (FDA) and is currently awaiting approval by Health Canada.

For more information: www.sjm.com

Related Content

Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019
Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device trial that, in addition...
 Tiny Wearable Cameras May Improve Quality of Life in Heart Failure Patients

Image courtesy of Amazon.com

News | Heart Failure | September 11, 2019
The ever-present devices that seem to track all our moves can be annoying, intrusive or worse, but for heart failure...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint of reducing total...
Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
News | Heart Failure | September 09, 2019
AstraZeneca announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga (dapagliflozin) on...
Dapagliflozin, Forxiga, was found to help improve outcomes in heart failure patients with reduced ejection fraction (HFrEF) at ESC 2019. #ESC19 #ESC2019
News | Heart Failure | September 09, 2019
September 9, 2019 — The drug Dapagliflozin was found to reduce death and hospitalization in patients who have heart f
Entresto Improved Measures of Heart Structure and Function in Heart Failure Patients
News | Heart Failure | September 04, 2019
September 4, 2019 – Novartis announced results from two new...
FDA Approves Barostim Neo System for Advanced Heart Failure Patients. Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels.

Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels and inhibit the production of stress-related hormones to reduce heart failure symptoms.

Technology | Heart Failure | August 19, 2019
The U.S. Food and Drug Administration (FDA) approved the Barostim Neo System for the improvement of symptoms in...
Ancora Heart Enrolls First Patient in European Multi-center Study of AccuCinch Heart Failure Therapy
News | Heart Failure | August 14, 2019
Ancora Heart Inc. announced the first patient was enrolled in the CorCinch EU study, a European multi-center clinical...
Procyrion Receives FDA Breakthrough Device Designation for Aortix System
Technology | Heart Failure | July 30, 2019
Procyrion Inc. secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its Aortix...
American Heart Association Introduces New Post-acute Care Heart Failure Certification
News | Heart Failure | July 03, 2019
The new Post-Acute Care Heart Failure Certification offered from the American Heart Association (AHA) provides...
Overlay Init